Clinical effect of therapy with high-dose recombinant human erythropoietin on cancer-related anemia

Objective:To compare the clinical effect of common-dose recombinant human erythropoietin(rhEPO)with high-dose rhEPO on anemia with malignancies.Methods:Anemic patients with malignancies were divided randomly into the control group(rhEPO 40 000U administered weekly for 7 times)and the experiment group(rhEPO 40 000 U administered in days 1,4,7,10,13,20,27,34,41).Clinical observations were performed every 2 weeks.Results:Hemoglobin level of the experiment group increased significantly after 2 weeks,while that of the control group increased significantly after 4 weeks,the former was higher than the latter after 4,6,8 weeks.The effect rates of 2,4,6,8 weeks were 41.9%,64.5%,83.9% and 87.1% respectively in the experiment group,higher than 16.1%,32.3%,54.8% and 61.3% in the control group(P0.05).The experiment group was better than the control group in improving patients'qualities of life.There were no statistical differences in side effects and transfusion rates between the two groups(P0.05).Conclusion:The effect of rhEPO with high dose was better than rhEPO with common-dose on anemic patients with malignancies.